Charlotte Robinson

DocwireNews

Researchers led by James Tumlin presented updated data based on longer follow-up from the RUBY-3 phase 1b/2a study of povetacicept in an abstract at the International Society of Nephrology&nbsp; World Congress of Nephrology 2024. Initial results of RUBY-3 found that povetacicept 80 mg given subcutaneously once every 4 weeks showed good tolerability with multiple dosing and promising reductions in urine protein-to-creatinine ratio (UPCR) and galactose-deficient IgA1 (Gd-IgA1) in study participants with immunoglobulin A nephropathy (IgAN).RUBY-3 participants are aged &ge;18 years with biopsy-confirmed IgAN, lupus nephritis, and primary membranous nephropathy, on maximally tolerated angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy, and with well-controlled blood pressure and disease-specific immunosuppressive therapy as applicable. They receive povetacicept 80 or 240 mg subcutaneously once every 4 weeks. The primary objective of the study is safety; efficacy is among the secondary objectives.As of December 1, 2023, 12 participants were enrolled and receiving povetacicept 80 mg; seven (58%) of them received &ge;24 weeks of treatment. Povetacicept has been well-tolerated, with no incidences of severe hypogammaglobulinemia (IgG &lt;3 g/L) or severe infections. Povetacicept 80 mg was associated with a UPCR reduction of 52.6% at 24 weeks (n=7) and with reductions in Gd-IgA1, stable renal function (based on estimated glomerular filtration rate), and pharmacodynamically expected decreases in immunoglobulin levels.In sum, povetacicept is well-tolerated with multiple dosing and shows promising activity in IgAN. These results support further study of povetacicept in IgAN and other glomerulonephritis and autoantibody-associated diseases.Source: <a href="https://doi.org/10.1016/j.ekir.2024.02.1411" target="_blank" rel="noopener">KI Reports</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Povetacicept Shows Promise for IgAN Treatment

WCN 2024

Longer follow-up results of the RUBY-3 trial found povetacicept is well-tolerated and shows promise for immunoglobulin A nephropathy (IgAN) treatment.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe